Aptamer-decorated nanocarriers for viral adsorption: A special look at COVID-19

IF 6.5 2区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Molecular Therapy. Nucleic Acids Pub Date : 2024-08-15 DOI:10.1016/j.omtn.2024.102310

Somayeh Handali, Mohsen Rezaei

引用次数: 0

Abstract

Viral infections are one of the leading causes of death in the world. One main challenge in fighting against these diseases is the unavailability of effective eradicating drugs and specific treatments. Nanocarriers and aptamer-decorated nanocarriers are designed to attach to many targets, including viral particles. By lowering the viral infectivity and attachment capability, they add therapeutic values even without containing antiviral drugs. Nevertheless, the nanoparticles (NPs) with encapsulated antiviral drugs can display extra therapeutic effects. Furthermore, it has been shown that aptamers can bind to viral particles and nanocarriers, presenting promising approaches for the identification of viruses and treatment of viral infections. Although there is no satisfying literature revealing the strong therapeutic potential of nanotechnology against COVID-19, the following information can provide new perspectives for upcoming investigations pertaining to developing effective aptamer-nanocarrier agents against COVID-19.

查看原文本刊更多论文

用于病毒吸附的色素修饰纳米载体：特别关注 COVID-19

病毒感染是世界上导致死亡的主要原因之一。抗击这些疾病的一个主要挑战是缺乏有效的根除药物和特效疗法。纳米载体和由适配体装饰的纳米载体可附着在包括病毒颗粒在内的许多目标上。通过降低病毒的感染性和附着能力，即使不含抗病毒药物，它们也能增加治疗价值。然而，封装了抗病毒药物的纳米颗粒（NPs）可以显示出额外的治疗效果。此外，已有研究表明，适配体能与病毒颗粒和纳米载体结合，为病毒的识别和病毒感染的治疗提供了有前景的方法。虽然目前还没有令人满意的文献揭示纳米技术对 COVID-19 的强大治疗潜力，但以下信息可为即将开展的有关开发有效抗 COVID-19 的适配体-纳米载体制剂的研究提供新的视角。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Therapy. Nucleic Acids MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

15.40

自引率

1.10%

发文量

336

审稿时长

20 weeks

期刊介绍： Molecular Therapy Nucleic Acids is an international, open-access journal that publishes high-quality research in nucleic-acid-based therapeutics to treat and correct genetic and acquired diseases. It is the official journal of the American Society of Gene & Cell Therapy and is built upon the success of Molecular Therapy. The journal focuses on gene- and oligonucleotide-based therapies and publishes peer-reviewed research, reviews, and commentaries. Its impact factor for 2022 is 8.8. The subject areas covered include the development of therapeutics based on nucleic acids and their derivatives, vector development for RNA-based therapeutics delivery, utilization of gene-modifying agents like Zn finger nucleases and triplex-forming oligonucleotides, pre-clinical target validation, safety and efficacy studies, and clinical trials.